Ionis Partner Roche Reports Sefaxersen Reduced Proteinuria 43.1% in Phase 3 IgAN Study
Roche’s Phase 3 study found investigational sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks in adults with IgA nephropathy, Ionis reported.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.